JP7232531B2 - 高忠実度ｃａｓ９バリアントおよびそれらの利用 - Google Patents

高忠実度ｃａｓ９バリアントおよびそれらの利用 Download PDF

Info

Publication number
JP7232531B2
JP7232531B2 JP2019565062A JP2019565062A JP7232531B2 JP 7232531 B2 JP7232531 B2 JP 7232531B2 JP 2019565062 A JP2019565062 A JP 2019565062A JP 2019565062 A JP2019565062 A JP 2019565062A JP 7232531 B2 JP7232531 B2 JP 7232531B2
Authority
JP
Japan
Prior art keywords
cas9 protein
mutations
mutation
modified cas9
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019565062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507347A5 (https=
JP2020507347A (ja
Inventor
チェレゼート，アンナ
カッシーニ，アントニオ
ペトリス，ジャンルカ
インガ，アルベルト
オリヴィエリ，ミケーレ
Original Assignee
ウニヴェルシタ デリ ストゥディ ディ トレント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴェルシタ デリ ストゥディ ディ トレント filed Critical ウニヴェルシタ デリ ストゥディ ディ トレント
Publication of JP2020507347A publication Critical patent/JP2020507347A/ja
Publication of JP2020507347A5 publication Critical patent/JP2020507347A5/ja
Application granted granted Critical
Publication of JP7232531B2 publication Critical patent/JP7232531B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019565062A 2017-02-14 2018-02-14 高忠実度ｃａｓ９バリアントおよびそれらの利用 Active JP7232531B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102017000016321 2017-02-14
IT102017000016321A IT201700016321A1 (it) 2017-02-14 2017-02-14 Mutanti di cas9 ad alta specificita' e loro applicazioni.
PCT/EP2018/053717 WO2018149888A1 (en) 2017-02-14 2018-02-14 High-fidelity cas9 variants and applications thereof

Publications (3)

Publication Number Publication Date
JP2020507347A JP2020507347A (ja) 2020-03-12
JP2020507347A5 JP2020507347A5 (https=) 2021-05-06
JP7232531B2 true JP7232531B2 (ja) 2023-03-03

Family

ID=59067822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565062A Active JP7232531B2 (ja) 2017-02-14 2018-02-14 高忠実度ｃａｓ９バリアントおよびそれらの利用

Country Status (12)

Country Link
US (1) US11525127B2 (https=)
EP (1) EP3583209B8 (https=)
JP (1) JP7232531B2 (https=)
KR (1) KR20190116407A (https=)
CN (1) CN110520528B (https=)
AU (1) AU2018221644A1 (https=)
BR (1) BR112019016765A2 (https=)
CA (1) CA3053218A1 (https=)
EA (1) EA037825B1 (https=)
IT (1) IT201700016321A1 (https=)
MX (1) MX2019009651A (https=)
WO (1) WO2018149888A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
CN108026526B (zh) 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20260019012A (ko) 2016-10-07 2026-02-09 인티그레이티드 디엔에이 테크놀로지스 아이엔씨. Ｓ. 피오게네스 ｃａｓ９ 돌연변이 유전자 및 이에 의해 암호화되는 폴리펩티드
US11242542B2 (en) * 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US11377645B2 (en) 2016-12-16 2022-07-05 The Rockefeller University Compositions and methods using Cas9 with enhanced spacer acquisition function
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
JP7229923B2 (ja) 2017-01-06 2023-02-28 エディタス・メディシン、インコーポレイテッド ヌクレアーゼ切断を評価する方法
IT201700016321A1 (it) 2017-02-14 2018-08-14 Univ Degli Studi Di Trento Mutanti di cas9 ad alta specificita' e loro applicazioni.
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
MX2019014640A (es) 2017-06-09 2020-10-05 Editas Medicine Inc Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP4253549A3 (en) * 2018-09-19 2023-12-06 The University of Hong Kong Improved high-throughput combinatorial genetic modification system and optimized cas9 enzyme variants
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US20220249625A1 (en) * 2019-01-29 2022-08-11 Flagship Pioneering Innovations V, Inc. Compositions comprising an endonuclease and methods for purifying an endonuclease
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3983542A2 (en) 2019-06-17 2022-04-20 CRISPR Therapeutics AG Methods and compositions for improved homology directed repair
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP7680440B2 (ja) * 2019-10-15 2025-05-20 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 核酸修飾酵素活性を測定するためのアッセイ法
WO2021122944A1 (en) 2019-12-18 2021-06-24 Alia Therapeutics Srl Compositions and methods for treating retinitis pigmentosa
US20230058352A1 (en) * 2020-03-11 2023-02-23 Sigma-Aldrich Co. Llc High Fidelity SpCas9 Nucleases for Genome Modification
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
WO2022133246A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CN112680430B (zh) * 2020-12-28 2023-06-06 南方医科大学 一种CRISPR SpCas9突变体及其应用
CN113005141A (zh) * 2021-01-05 2021-06-22 温州医科大学 高活性突变体构成的基因编辑工具及制备方法和修复先天性视网膜劈裂症致病基因的方法
WO2022152746A1 (en) 2021-01-13 2022-07-21 Alia Therapeutics Srl K526d cas9 variants and applications thereof
CN112626070A (zh) * 2021-01-13 2021-04-09 海南微氪生物科技股份有限公司 一种基于切离酶基因编辑技术的定向修复系统
WO2022238958A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Multiplex gene editing
WO2023285431A1 (en) 2021-07-12 2023-01-19 Alia Therapeutics Srl Compositions and methods for allele specific treatment of retinitis pigmentosa
EP4413146A2 (en) * 2021-10-05 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Treatment of polycythemia vera via crispr/aav6 genome editing
CN120225668A (zh) * 2023-10-25 2025-06-27 石药集团中奇制药技术（石家庄）有限公司 一种高效低脱靶的基因编辑工具
CN117887760A (zh) * 2024-01-22 2024-04-16 中国医学科学院北京协和医院 SQSTM1/p62基因新致病突变c.1143delC的敲入小鼠模型及其构建方法
CN118497204B (zh) * 2024-07-16 2024-12-03 西北农林科技大学深圳研究院 一种质粒CRISPR-pCas9n及基因编辑的方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205613A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzyme mutations reducing off-target effects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3004339B1 (en) * 2013-05-29 2021-07-07 Cellectis New compact scaffold of cas9 in the type ii crispr system
EP3250689B1 (en) * 2015-01-28 2020-11-04 The Regents of The University of California Methods and compositions for labeling a single-stranded target nucleic acid
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
US11214779B2 (en) * 2015-04-08 2022-01-04 University of Pittsburgh—of the Commonwealth System of Higher Education Activatable CRISPR/CAS9 for spatial and temporal control of genome editing
US9512446B1 (en) * 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
IT201700016321A1 (it) 2017-02-14 2018-08-14 Univ Degli Studi Di Trento Mutanti di cas9 ad alta specificita' e loro applicazioni.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205613A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzyme mutations reducing off-target effects

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Human Gene Therapy (2016) Vol.27, No.11, p.A41, OR50
Nature (2016) Vol.529, pp.490-495, METHODS, Extended Data Figure 1-9 and Table 1
Science (2016) Vol.351, No.6268, pp.84-88

Also Published As

Publication number Publication date
EA037825B1 (ru) 2021-05-25
CN110520528B (zh) 2024-08-13
EP3583209B8 (en) 2025-02-26
WO2018149888A1 (en) 2018-08-23
MX2019009651A (es) 2019-12-18
CA3053218A1 (en) 2018-08-23
US11525127B2 (en) 2022-12-13
EP3583209C0 (en) 2024-12-04
IT201700016321A1 (it) 2018-08-14
EP3583209A1 (en) 2019-12-25
BR112019016765A2 (pt) 2020-05-26
EP3583209B1 (en) 2024-12-04
EA201991913A1 (ru) 2020-01-22
AU2018221644A1 (en) 2019-08-29
JP2020507347A (ja) 2020-03-12
KR20190116407A (ko) 2019-10-14
CN110520528A (zh) 2019-11-29
US20200149020A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP7232531B2 (ja) 高忠実度ｃａｓ９バリアントおよびそれらの利用
JP7585373B2 (ja) 変更ＰＡＭ特異性を有する遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
JP6745391B2 (ja) 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
AU2018341985B2 (en) CRISPR/Cas system and method for genome editing and modulating transcription
US12054754B2 (en) CRISPR-associated transposon systems and components
CN105517579B (zh) 用于RNA向导的基因调节和编辑的正交Cas9蛋白
CA3111432A1 (en) Novel crispr enzymes and systems
WO2017219027A1 (en) Type vi crispr orthologs and systems
JP2024501892A (ja) 新規の核酸誘導型ヌクレアーゼ
Casini Better safe than sorry: new CRISPR/Cas9 tools for improved genome engineering
Glibauskaitė Directed evolution studies of a methylation-sensitive cas9 for human genome editing
WO2024030961A2 (en) Type lb crispr-associated transposase systems
CN117795085A (zh) 用于dna修饰的crispr-转座子系统
WO2024119052A2 (en) Genomic cryptography
HK1249132B (en) Engineered crispr-cas9 nucleases with altered pam specificity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230213

R150 Certificate of patent or registration of utility model

Ref document number: 7232531

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250